Why Lycia Therapeutics, Inc.’s (LYCA) Stock Is Up 6.74%
As of Wednesday, November 11, Lycia Therapeutics, Inc.’s LYCA share price has surged by 6.74%, which has investors questioning if this is right time to sell.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Tudor Pop
| Share Statistics | LYCA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,799.6 | $211.8 | 53% |
|
| Shares Out (Mil) | 14.5 | 55.4 | 26% |
|
| Institutional Ownership | 78.1% | 93.0% | 47% |
|
| Float (Mil) | 33.8 | 41.5 | 38% |
|
| Beta | na | 0.99 | na |
|
| Avg Daily Volume (000s) | 277 | 553 | 49% |
|
| Price Change (52-week) |
na | 42.8% | na |
|
| Growth | LYCA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | na | (10.3%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | LYCA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $4 | $41 | 5% |
|
| Net Income (TTM) (Mil) | ($30) | ($44) | 20% |
|
| EPS (TTM) | ($2.091) | ($1.500) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | ($34) | ($35) | 12% |
|
| Net Cash Flow (TTM) (Mil) | $36 | $-0 | 68% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $4 | 19% |
|
| Enterprise Value (Q1) (Mil) | $1,732 | $147 | 48% |
|
| Valuation | LYCA | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.01 | na |
|
| P/E | na | 17.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | LYCA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 291.5% | 67.9% | 100% |
|
| Net Margin | (677.2%) | (50.6%) | 1% |
|
| ROA | (38.3%) | (47.4%) | 14% |
|
| ROE | 45.5% | (53.1%) | 92% |
|
| Liabilities to Assets | 7.6% | 29.7% | 4% |
|
| F-Score | 0 | 3 | na |
|
Lycia Therapeutics, Inc. did not pass any screens on 11/13/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors